Pharmaceutical products: 70%
Health and care products: 20%
Dietary supplements: 10%

Brazil: 65%
Argentina: 15%
Mexico: 10%

Hypera S.A. generates the majority of its revenue from the sale of pharmaceutical products, which account for approximately 70% of total revenue. The remainder is distributed among health and care products as well as dietary supplements.

Geographically, Brazil is the main market for Hypera S.A., followed by Argentina and Mexico. These markets are crucial for the company as they together make up 90% of the revenue. The strong presence in these countries is attributed to the strategic focus and targeted expansion in Latin America.

Production Sites: São Paulo, Brazil

Hypera S.A. is one of the leading pharmaceutical companies in Brazil and has its main production facilities in São Paulo. This strategic location allows the company to react efficiently to the Brazilian market while optimizing logistics costs.

The company focuses on manufacturing pharmaceutical products, including over-the-counter medications and generics, and utilizes state-of-the-art technologies to ensure the quality and efficiency of its production processes.

Revenue Growth: Estimated 10% annually (2026)

Focus on Research and Development: 8% of revenue (2026)

Hypera S.A. pursues a growth strategy that heavily emphasizes innovation and expansion into new markets. The company invests significantly in research and development to expand its product range and offer new, innovative healthcare solutions.

Another strategic focus is on geographical expansion, particularly in emerging markets, to strengthen market presence. Through targeted acquisitions and partnerships, Hypera plans to further enhance its market position in Latin America.

Additionally, the company is focusing on digital transformation and expanding its online distribution channels to improve customer access and increase efficiency. These measures are intended to sustainably support revenue growth and ensure the competitiveness of Hypera S.A.

Main raw materials: Pharmaceutical active ingredients, packaging materials
Main importing countries: China, India, Germany

Hypera S.A. mainly imports pharmaceutical active ingredients that are necessary for the production of their products. These active ingredients are predominantly sourced from China and India, as these countries are leading in the production of generic active ingredients.

In addition, the company imports packaging materials that are required for the safe and effective packaging of their pharmaceutical products. These materials often come from Germany, which is known for its high-quality packaging solutions.

The dependence on these imports is characteristic of the pharmaceutical industry, which relies on specialized supply chains to ensure the quality and effectiveness of its products.

Market share: 12% (estimated, 2026)
EBITDA margin: 30% (2025)
Research and development expenditure: 5% of revenue (2025)

Hypera S.A. has a significant competitive advantage in the Brazilian pharmaceutical market, highlighted by an estimated market share of 12% in 2026. The company benefits from a strong brand presence and a diversified product portfolio that includes both prescription and over-the-counter medications.

The EBITDA margin of 30% in 2025 demonstrates the efficiency and profitability of Hypera S.A., indicating effective cost control and strong pricing power. This margin is above average compared to many competitors in the industry.

Another important aspect of the competitive advantage is the continuous focus on research and development, evidenced by the expenditure of 5% of revenue in 2025. These investments enable Hypera to develop innovative products and differentiate itself in a competitive market.

Institutional Investor Share: approximately 45% (2026, estimated)

Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Hypera S.A. is around 45%, indicating a strong trust from institutional investors in the company. These investors typically include pension funds, investment funds, and other large financial institutions that prefer long-term holdings.

In 2025, there were no significant insider buys or sells, suggesting that the management and other insiders have a stable confidence in the company's future development. Such transactions are often seen as an indicator of the management's assessment of the company's value.

Market share of Hypera S.A.: 12% (estimated, 2026)

Top competitors and their market shares:

1. EMS Pharma: 18%
2. Sanofi Brasil: 15%
3. Aché Laboratórios: 13%
4. Hypera S.A.: 12%
5. Eurofarma: 10%
6. Novartis Brasil: 9%
7. Pfizer Brasil: 8%
8. Bayer Brasil: 7%
9. GlaxoSmithKline Brasil: 5%
10. Roche Brasil: 3%

Hypera S.A. is one of the leading players in the Brazilian pharmaceutical market. The 12% market share indicates that the company plays a significant role, although it lags behind EMS Pharma and Sanofi Brasil.

Hypera S.A.'s moat mainly consists of a strong brand presence and a wide product portfolio that includes both over-the-counter and prescription drugs. Compared to its competitors, Hypera has the advantage of deep roots in the Brazilian market and strong brand recognition.

However, some of the international competitors like Sanofi and Pfizer may have a stronger moat in terms of global research capabilities and innovation power. These companies can leverage their global presence and extensive research and development resources to bring new products to market faster.

Overall, Hypera S.A. has a solid, though not insurmountable, moat supported by local market knowledge and brand strength. The competition remains strong, especially due to the innovation and global reach of international pharmaceutical companies.

Revenue Growth: 8.5% (2025)
Profit Growth: 7.2% (2025)
Market Share in the Brazilian Pharmaceutical Sector: 12% (2025)

Hypera S.A. has experienced solid revenue and profit growth in recent years. The company benefits from a strong market position in the Brazilian pharmaceutical sector, where it holds approximately 12% of the market share. This position enables Hypera to benefit from the increasing demand for pharmaceutical products in Brazil.

The company continuously invests in research and development, indicating a long-term growth strategy. Additionally, in recent years, Hypera has diversified its product range, reducing risk and opening up additional growth opportunities.

The economic conditions in Brazil are stable, and the healthcare industry shows sustained growth potential. This could help Hypera further expand its market position. Analysts view the strategic direction and investments in new technologies and markets as positive indicators for future growth.

Dividend Yield: 4.5% (estimated for 2026)
Dividend Reliability: High

Hypera S.A. has regularly distributed dividends in the past and is known for its reliable dividend policy. The company has a strong financial foundation and a solid market position, allowing it to continuously pay dividends to its shareholders.

The estimated dividend yield of 4.5% for 2026 is based on historical payouts and the company's current financial indicators. Analysts expect that Hypera S.A. will maintain a stable dividend policy in the coming years, supported by a robust business model and a healthy balance sheet.